According to the National Poll on Healthy Aging, nearly 60% of older adults with obesity were interested in a weight management drug. Over three-fourths of surveyed seniors thought Medicare should ...

— Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight at 12 months compared with DELI ...

CAMPBELL, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments ...

(MENAFN- GlobeNewsWire - Nasdaq) - Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight ...

Community Word is published monthly by Community Word LLC. Independently owned by local investors. Brian Ludwig, Managing Editor, c/o 621 Commercial St. Suite 1A-B, Peoria, IL 61602, ...

The FDA is requesting that drugmakers remove suicidal ideation and behavior warnings from the labeling of three GLP-1 receptor agonists — Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has requested mention of risk for suicidal ...

The FDA requested that manufacturers of GLP-1 receptor agonists (RAs) remove the warning regarding the risk of suicidal ideation and behavior (SI/B) from the drugs’ labeling. In July 2023, after ...

Regulator asks drugmakers to remove warnings of suicidal thoughts from GLP-1 drugs' labels FDA finds no link between GLP-1 drugs and suicidal thoughts Novo Nordisk and Eli Lilly welcome FDA's ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and ...